Tomographic imaging with radionuclides actually predates CT, with early attempts dating from 1963 [2].
In this review, nanostructures labeled with radionuclides were introduced for in vivo tumor imaging.
Dedicated high resolution detectors are needed for detection of small tumors by molecular imaging with radionuclides.
Molecular Breast Imaging with radionuclides has a central role to play in this respect.
BODIPY derivatives have also been radiolabeled with radionuclides for the development of bimodal PET and fluorescent imaging agents.
Synthetic groundwaters were spiked with radionuclides and surrogate species at the appropriate amount to achieve the target concentration (Table 3).
Furthermore, the peptide targeted against c-MET was also labeled with radionuclides (18F, 99mTc) to detect expression of c-MET.
For this, the molecularly targeting therapeutic agents are labeled with radionuclides to be used as PET tracers [2].
Molecular imaging with radionuclides is a very sensitive technique because it allows to obtain images with nanomolar or picomolar concentrations.
In vivo imaging of pharmaceuticals labeled with radionuclides has proven to be a powerful tool in human subjects.
Dedicated high-resolution detectors are required for detection of small cancerous breast tumours by molecular imaging with radionuclides.
